<DOC>
	<DOCNO>NCT01484314</DOCNO>
	<brief_summary>Eltrombopag compound may help stimulate production platelet . This drug use treatment low platelet count cause disorder call idiopathic thrombocytopenic purpura information research study suggest Eltrombopag may help maintain platelet count patient relapse multiple myeloma research study . In research study , investigator try determine Eltrombopag effective maintain platelet count patient treat relapsed multiple myeloma .</brief_summary>
	<brief_title>Eltrombopag Thrombocytopenia Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>You take eltrombopag two consecutive cycle chemotherapy . During two cycle ask complete follow research study addition clinical exam procedure regular doctor may order : Study Drug ( ) : If take part research study , give study drug-dosing calendar treatment cycle . Each treatment cycle last 27 day time take study drug 11 day day 1 11 . Clinical Exams : You physical exam day 1 , 11 , 21 cycle . You ask question general health specific question problem might medication may take . Your vital sign collect exam . Performance status : Your ability perform daily task assess day 1 27 cycle . Blood Tests : You test check safety perform day 1 , 7 , 11 , 20 , 27 cycle . You approximately 1-2 teaspoon blood collect . Concurrent Medications : Any change medication record . Adverse Events : You continually monitor change health well-being study . You complete subsequent cycle chemotherapy procedure per standard care DFCI . During subsequent cycle , take eltrombopag . After final dose study drug : On Day 1 cycle 3 chemotherapy , complete end study/off study evaluation . The following procedure complete : - Physical Exam , include vitals sign - Performance status , evaluate able carry usual activity . - Tumor Measurements : We assess tumor blood test and/or bone marrow aspirate biopsy . If clinically indicate , may CT scan , bone scan skeletal survey - Blood test , routine test check safety - Concurrent Medications : Any change medication record . Follow-up : We would also like keep track medical condition thirty day last dose study drug . We would like return blood count check week 4 week call check condition change health well-being may occur since last take study drug .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Participants must histologically confirm multiple myeloma relapse refractory Patients may 1 prior chemotherapy regimens multiple myeloma none within precede 14 day Performance status ( ECOG ) ≤ 2 Not pregnant breastfeed Participants history rapidly progressive disease [ increase tumor size ( ≥ 50 % ) define standard myeloma marker ] , pelvic irradiation , chemotherapy radiotherapy within precede 14 day Participants may receive study agent within 21 day prior entry study . The use growth factor erythropoiesis stimulate agent GCSF ( Neupogen Neulasta ) study period . Participants evidence active thromboembolic disease history thromboembolism within precede 6 month ( exclude thrombosis central line ) . Participants document history genetic predisposition thrombosis ( antiphospholipid antibody syndrome , ATIII deficiency , etc . ) , platelet disorder bleed disorder . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within precede 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed</keyword>
</DOC>